Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1644 1646 1647 1654 1674
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18283575 | METHODS AND AGENTS FOR MODULATING ADOPTIVE IMMUNOTHERAPY | Non-Final OA | The Regents of the University of California |
| 18043878 | A BROADLY NEUTRALIZING MOLECULE AGAINST CLOSTRIDIUM DIFFICILE TOXIN B | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17752407 | ENCODING HIERARCHICAL ASSEMBLY PATHWAYS OF PROTEINS WITH DNA | Non-Final OA | NORTHWESTERN UNIVERSITY |
| 18263929 | TREATMENT OF CVD AND SYSTEMIC SCEROSIS WITH BETA-1 ADRENERGIC RECEPTOR ANTIBODIES | Non-Final OA | The Cleveland Clinic Foundation |
| 18034326 | USE OF AN IL-18 ANTAGONIST FOR TREATING AND/OR PREVENTION OF ATOPIC DERMATITIS OR A RELATED CONDITION | Final Rejection | NOVARTIS AG |
| 17877814 | COMPOSITIONS COMPRISING EXTRACELLULAR VESICLES, SECRETED BIOMOLECULES, AND/OR CONDITIONED MEDIA, AND METHODS OF PRODUCING AND USING THE SAME | Final Rejection | L'Oreal |
| 17767810 | Artificial Transmembrane Proteins for Detecting Intracellular or Intravesicular Biomolecular Interactions | Final Rejection | Hoffmann-La Roche Inc. |
| 18297805 | SOLUBLE TREM2 PROTEIN AND USES THEREOF | Final Rejection | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18169497 | COMBINATION THERAPIES FOR TREATMENT OF CANCER WITH THERAPEUTIC BINDING MOLECULES | Final Rejection | MedImmune Limited |
| 18515636 | MonoMac-1 Cells Expressing CD16 and CD163 | Non-Final OA | Temple University-Of The Commonwealth System of Higher Education |
| 18035356 | Methods and compositions for eliminating engineered immune cells | Non-Final OA | Miltenyi Biotec B.V. & Co. KG |
| 18178783 | COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF | Non-Final OA | MACROGENICS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy